Revance(US:RVNC) Prnewswire·2025-02-07 10:45Core Points - A class action securities lawsuit has been filed against Revance Therapeutics, Inc. for alleged securities fraud affecting investors between February 29, 2024, and December 6, 2024 [1][2] - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted exclusive rights to market and distribute Teoxane's dermal fillers, leading to increased litigation risks and potential harm [2] - Investors have until March 4, 2025, to request to be appointed as lead plaintiff, with no costs required to participate in the lawsuit [3] Company Details - Revance Therapeutics is facing allegations that its public statements were materially false and misleading, which could have significant implications for its reputation and financial standing [2] - The lawsuit highlights the potential for monetary and reputational harm due to the alleged breach of agreement with Teoxane [2] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]